NCT04222465 (CHRISTELLE) is a clinical trial in Ovarian Neoplasms, sponsored by AstraZeneca.

Who is sponsoring NCT04222465?

NCT04222465 is sponsored by AstraZeneca.

What condition does NCT04222465 study?

NCT04222465 studies Ovarian Neoplasms.

Is NCT04222465 still recruiting?

NCT04222465 is currently completed. Last updated 26 October 2021.

Last reviewed 2021-10-26 · How we verify

NCT04222465: CHRISTELLE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients

Completed Last updated 26 October 2021

What this trial tests

trial in Ovarian Neoplasms in 207 participants. Completed in 13 November 2020.

Timeline

19 March 2020

Primary endpoint
13 November 2020

13 November 2020

Quick facts

Lead sponsor	AstraZeneca
Status	Completed
Study type	OBSERVATIONAL
Enrollment	207
Start date	19 March 2020
Primary completion	13 November 2020
Estimated completion	13 November 2020
Sites	20 locations across Japan

Conditions studied

Ovarian Neoplasms — all drugs for Ovarian Neoplasms →

Sponsor

AstraZeneca — full company profile →

Who can join

20 and older, female only, with Ovarian Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, observational study in Japan. Patients with newly diagnosed FIGO stage III - IV advanced OC will be enrolled sequentially. In this study, data of 200 subjects will be collected at approximately 20 sites in Japan. To reduce regional bias of study sites, the number of enrolled patients per site will be capped

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial.
Fujiwara K, Fujiwara H, Yoshida H, Satoh T, et al · · 2021 · cited 11× · PMID 34378365 · DOI 10.3802/jgo.2021.32.e82

Verify or expand the search:

Other recruiting trials for Ovarian Neoplasms

Currently open trials in the same condition.

NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07280312 — Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions · NA · recruiting
NCT07038369 — A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · Phase 1 · active not recruiting
NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
NCT06751329 — A Study of DM002 in Patients With Advanced Solid Tumors · Phase 1 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04222465 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 26 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04222465.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing